AbbVie Pinpoints US Humira Erosion At 37% In 2023

 
• By Joseph Haas
  
Biosimilar
With the first Humira biosimilar on the US market, AbbVie addressed investor concerns • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business